Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep (NASDAQ: IMMP) announced an abstract has been accepted for poster presentation at the ASCO 2026 Annual Meeting in Chicago, 29 May–2 June 2026.

Rhea-AI Summary

Immutep (NASDAQ: IMMP) announced an abstract has been accepted for poster presentation at the ASCO 2026 Annual Meeting in Chicago, 29 May–2 June 2026. The poster, titled “Impact of eftilagimod alfa…on lymphocyte activation and survival outcomes in metastatic cancer patients,” is scheduled for 30 May 2026, 1:30 PM–4:30 PM CDT, Poster Board 359, Abstract #2569.

The presentation will report cumulative clinical and translational data across multiple late-stage cancer studies indicating that eftilagimod alfa (efti), an APC activator via MHC class II, induces rapid and sustained lymphocyte activation associated with improved overall survival in metastatic patients.

Argus Apr 22 session

+0.41% close to close Open Argus

Details

News Market Reaction – IMMP

On Apr 22, the day this news came out, IMMP closed 0.41% above the previous close.

Data tracked by StockTitan Argus for the Apr 22 session.

Key Figures

ASCO 2026 dates: 29 May–2 June 2026 Poster session time: 30 May 2026, 1:30 PM–4:30 PM CDT Poster board: 359 +1 more

ASCO 2026 dates

29 May–2 June 2026

American Society of Clinical Oncology Annual Meeting schedule

Poster session time

30 May 2026, 1:30 PM–4:30 PM CDT

ASCO 2026 poster presentation slot

Poster board

359

Assigned poster board number at ASCO 2026

Abstract number

2569

ASCO 2026 abstract identifier

Historical Context

5 past events · Latest: Apr 15

5 events

1. Apr 15

   Orphan designation win

   24h Move

   +72.8%

   FDA Orphan Drug Designation for efti in soft tissue sarcoma.

2. Mar 19

   Phase I progress

   24h Move

   -0.7%

   Successful SAD completion and MAD progression for IMP761 in Phase I.

3. Mar 13

   Phase III futility stop

   24h Move

   -82.4%

   TACTI-004 Phase III NSCLC study discontinued after futility analysis.

4. Feb 06

   Phase III enrolment

   24h Move

   +0.0%

   TACTI-004 Phase III trial reached 50% enrolment and futility remains on track.

5. Jan 29

   Quarterly update

   24h Move

   -2.9%

   Quarterly report with major efti licensing deal and extended cash runway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunotherapy, antigen-presenting cell, apc activator, mhc class ii, +3 more

7 terms

immunotherapy medical

"a clinical-stage immunotherapy company targeting cancer and autoimmune diseases"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

antigen-presenting cell medical

"eftilagimod alfa (efti), an antigen-presenting cell (APC) activator targeting MHC Class II"

An antigen-presenting cell is an immune cell that captures a foreign substance, breaks it into small pieces and displays those pieces on its surface to alert and activate other immune cells — like a guard pinning a wanted poster so the rest of the army knows what to look for. Investors care because these cells are central to how vaccines, cancer immunotherapies and some diagnostics work; differences in how well they function can drive clinical trial results, regulatory decisions and the commercial value of medical products.

apc activator medical

"eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation"

An APC activator is a drug or biological agent that stimulates antigen-presenting cells — immune cells that capture foreign material and show pieces of it to other immune cells to trigger a response. For investors, APC activators matter because they can boost vaccine effectiveness or cancer immunotherapy, potentially increasing a product’s clinical value and market potential; think of them as coaching a team’s scout to better spot and signal threats to the rest of the immune system.

mhc class ii medical

"an APC activator via MHC class II, on lymphocyte activation and survival outcomes"

MHC class II are proteins displayed on the surface of certain immune cells that show small fragments of foreign or internal proteins to immune “coordinator” cells, triggering and shaping immune responses. For investors, changes in MHC class II activity or targeting by drugs and vaccines can determine how well a therapy activates or dampens the immune system, influencing clinical effectiveness, safety, and regulatory approval — similar to how a lock-and-key system controls access.

lymphocyte medical

"induces rapid and sustained lymphocyte activation"

A lymphocyte is a type of white blood cell that acts like a body's security guard, identifying and helping remove infections, abnormal cells, or foreign substances. For investors, lymphocyte counts matter because they are common safety and efficacy measures in clinical trials and ongoing drug monitoring: changes can signal immune effects, side effects, or therapeutic activity that influence regulatory decisions, trial outcomes, and a treatment's market prospects.

metastatic medical

"survival outcomes in metastatic cancer patients"

Metastatic describes cancer that has spread from its original spot to other organs or tissues, like weeds moving from one garden bed into several others. For investors, metastatic disease matters because it often requires more complex, long-term treatments, larger clinical trials, and can drive demand for specialized drugs and diagnostics—factors that affect a drug’s development costs, regulatory risk, market size, and potential revenue.

overall survival medical

"immune activation markers were associated with improved overall survival outcomes"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States).

The accepted abstract, titled “Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients,” will be presented within the Developmental Therapeutics—Immunotherapy sessions by Professor Martin Forster from the UCL Cancer Institute, UK.

The poster will present cumulative clinical and translational data demonstrating that eftilagimod alfa (efti), an antigen-presenting cell (APC) activator targeting MHC Class II, induces rapid and sustained lymphocyte activation. Across multiple late-stage cancer studies¹, immune activation markers were associated with improved overall survival outcomes in patients with metastatic disease, supporting the clinical relevance of eftilagimod alfa’s mechanism of action.

ASCO 2026 Poster Presentation Details

Title: Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients
Poster Session: Developmental Therapeutics—Immunotherapy
Date and Time: 30 May 2026, 1:30 PM-4:30 PM CDT
Poster Board: 359
Abstract #: 2569

About ASCO 2026

The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates and investment analysts to discuss cutting-edge clinical research and emerging therapeutics in oncology, and to gain insights to improve cancer care. More than 40,000 attendees from around the world are expected to participate in person and online to stay up to date on the latest advances across all areas of cancer research and to hear real-time insights from world-renowned experts. For additional information on the ASCO Annual Meeting, please visit www.asco.org.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com

This announcement was authorised for release by the CEO of Immutep Limited.

---

¹ Please note that the abstract does not include data from the TACTI-004 study, as immune data collection for that trial has not yet been completed. All data presented were collected from earlier clinical trials, initiated prior to TACTI-004.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Immutep (IMMP) present at ASCO 2026 and when is the poster session?

Immutep will present a poster on eftilagimod alfa’s immune effects on 30 May 2026, 1:30 PM–4:30 PM CDT. According to the company, Poster Board 359 (Abstract #2569) reports cumulative clinical and translational data from multiple late-stage cancer studies linking lymphocyte activation to survival.

What is the main finding about eftilagimod alfa in the IMMP ASCO 2026 abstract?

The abstract reports that eftilagimod alfa induces rapid, sustained lymphocyte activation associated with improved overall survival. According to the company, the poster pools data across multiple late-stage metastatic cancer studies supporting the mechanism of APC activation via MHC class II.

Who will present Immutep’s poster on eftilagimod alfa at ASCO 2026 (IMMP)?

Professor Martin Forster from the UCL Cancer Institute will present the poster on behalf of Immutep. According to the company, the presentation appears in the Developmental Therapeutics—Immunotherapy session at ASCO 2026.

How does the ASCO 2026 poster (IMMP) frame eftilagimod alfa’s mechanism of action?

The poster frames efti as an APC activator targeting MHC class II that triggers lymphocyte activation. According to the company, translational markers of immune activation across studies were associated with improved overall survival in metastatic patients.

Where and how can investors view Immutep’s (IMMP) ASCO 2026 poster presentation details?

Investors can view the poster in-person at ASCO Chicago on 30 May 2026, Poster Board 359, 1:30 PM–4:30 PM CDT. According to the company, the abstract is listed as #2569 in the Developmental Therapeutics—Immunotherapy session and may be available online via ASCO materials.